PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
PMV Pharmaceuticals (NASDAQ: PMVP) will present initial clinical data for rezatapopt at the AACR-NCI-EORTC conference in Boston on October 22–26, 2025. An oral presentation will report an initial analysis of the pivotal PYNNACLE Phase 2 trial in patients with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation on Friday, October 24 at 10:00–11:40 AM ET, presented by Dr. Alison M. Schram.
Two poster presentations will follow: the PYNNACLE initial analysis on Friday, October 24 (12:30–4:00 PM ET, Poster Session B, Exhibit Hall D) and a real-world natural history and prognostic study of TP53 Y220C on Saturday, October 25 (12:30–4:00 PM ET, Poster Session C, Exhibit Hall D).
PMV Pharmaceuticals (NASDAQ: PMVP) presenterà dati clinici iniziali su rezatapopt alla conferenza AACR-NCI-EORTC di Boston dal 22 al 26 ottobre 2025. Una presentazione orale riporterà una analisi iniziale del trial pivot PYNNACLE di fase 2 in pazienti con tumori solidi localmente avanzati o metastatici che ospitano una mutazione TP53 Y220C, venerdì 24 ottobre dalle 10:00 alle 11:40 ET, presentata dalla Dott.ssa Alison M. Schram.
Seguono due poster: l'analisi iniziale PYNNACLE venerdì 24 ottobre (12:30-16:00 ET, Poster Session B, Exhibit Hall D) e uno studio di storia naturale reale e prognostico della TP53 Y220C sabato 25 ottobre (12:30-16:00 ET, Poster Session C, Exhibit Hall D).
PMV Pharmaceuticals (NASDAQ: PMVP) presentará datos clínicos iniciales sobre rezatapopt en la conferencia AACR-NCI-EORTC en Boston del 22 al 26 de octubre de 2025. Una presentación oral reportará un análisis inicial del ensayo pivotal PYNNACLE de Fase 2 en pacientes con tumores sólidos localmente avanzados o metastáticos que albergan una mutación TP53 Y220C, el viernes 24 de octubre de 10:00 a 11:40 a.m. ET, presentado por la Dra. Alison M. Schram.
Seguirán dos pósters: el análisis inicial de PYNNACLE el viernes 24 de octubre (12:30-16:00 ET, Sesión de Póster B, Exhibit Hall D) y un estudio de historia natural real y pronóstico de TP53 Y220C el sábado 25 de octubre (12:30-16:00 ET, Sesión de Póster C, Exhibit Hall D).
PMV Pharmaceuticals (NASDAQ: PMVP)은 2025년 10월 22일부터 26일까지 보스턴에서 열리는 AACR-NCI-EORTC 컨퍼런스에서 rezatapopt의 초기 임상 데이터를 발표합니다. 구두 발표로 위험성 가설을 확인하는 PYNNACLE 2상 임상시험의 초기 분석이 현장에 보고되며, TP53 Y220C 돌연변이를 보유한 국소진행성 또는 전이성 고형암 환자에서 10월 24일 금요일 오전 10:00–11:40 ET에 Alison M. Schram 박사가 발표합니다.
이후 두 편의 포스터 발표가 이어집니다: 1) 금요일 10월 24일 12:30–16:00 ET, 포스터 세션 B, 전시관 D에서 PYNNACLE 초기 분석, 2) 토요일 10월 25일 12:30–16:00 ET, 포스터 세션 C, 전시관 D에서 TP53 Y220C의 실제 세계 자연사 및 예후 연구.
PMV Pharmaceuticals (NASDAQ: PMVP) présentera des données cliniques préliminaires sur rezatapopt lors de la conférence AACR-NCI-EORTC à Boston du 22 au 26 octobre 2025. Une présentation orale rendra compte d'une analyse préliminaire de l'essai pivot PYNNACLE de phase 2 chez des patients atteints de tumeurs solides localement avancées ou métastatiques présentant une mutation TP53 Y220C, le vendredi 24 octobre de 10h00 à 11h40 ET, présentée par le Dr Alison M. Schram.
Deux affiches suivront : l'analyse préliminaire PYNNACLE le vendredi 24 octobre (12h30-16h00 ET, Session d'Affiches B, Exhibit Hall D) et une étude de l'histoire naturelle réelle et du pronostic de TP53 Y220C le samedi 25 octobre (12h30-16h00 ET, Session d'Affiches C, Exhibit Hall D).
PMV Pharmaceuticals (NASDAQ: PMVP) wird auf der AACR-NCI-EORTC-Konferenz in Boston vom 22. bis 26. Oktober 2025 erste klinische Daten zu rezatapopt präsentieren. Eine mündliche Präsentation wird eine erste Analyse der pivotalen PYNNACLE-Phase-2-Studie bei Patienten mit lokal fortgeschrittenen oder metastatischen soliden Tumoren, die eine TP53 Y220C-Mutation tragen, am Freitag, den 24. Oktober von 10:00 bis 11:40 Uhr ET, vorgestellt von Dr. Alison M. Schram, berichten.
Zwei Posterfolgen folgen: die PYNNACLE-Erstanalyse am Freitag, 24. Oktober (12:30–16:00 ET, Poster Session B, Exhibit Hall D) und eine real-world Natural History und Prognose-Studie der TP53 Y220C am Samstag, 25. Oktober (12:30–16:00 ET, Poster Session C, Exhibit Hall D).
PMV Pharmaceuticals (NASDAQ: PMVP) ستقدم بيانات سريرية أولية عن rezatapopt في مؤتمر AACR-NCI-EORTC في بوسطن في الفترة من 22 إلى 26 أكتوبر 2025. ستعرض عرض شفوي التحليل الأولي من تجربة PYNNACLE Phase 2 الحاسمة لدى مرضى سرطان صلب محلياً متقدم أو منتشر مع وجود طفرة TP53 Y220C، يوم الجمعة 24 أكتوبر من الساعة 10:00 إلى 11:40 صباحاً بتوقيت شرق الولايات المتحدة، تقديم الدكتورة أليسون م. شراهم.
سيعقب ذلك عرضان باللوحات: التحليل الأولي لـ PYNNACLE يوم الجمعة 24 أكتوبر (12:30–16:00 ET، جلسة الملصقات B، قاعة المعارض D) ودراسة التاريخ الطبيعي الواقعي والتنبؤ لـ TP53 Y220C يوم السبت 25 أكتوبر (12:30–16:00 ET، جلسة الملصقات C، قاعة المعارض D).
PMV Pharmaceuticals (NASDAQ: PMVP) 将在波士顿举行的 AACR-NCI-EORTC 会议上于 2025 年 10 月 22-26 日公布 rezatapopt 的初步临床数据。一场口头报告将报道一个 PYNNACLE 二期关键试验的初步分析，对象为携带 TP53 Y220C 突变 的局部晚期或转移性实体肿瘤患者，时间为 2025 年 10 月 24 日（星期五）美国东部时间 10:00–11:40，由 Alison M. Schram 博士主持。
随后将有两场海报报告：1) 10 月 24 日（星期五）12:30–16:00 ET，海报环节 B，展览馆 D，PYNNACLE 初步分析；2) 10 月 25 日（星期六）12:30–16:00 ET，海报环节 C，展览馆 D，TP53 Y220C 的真实世界自然史和预测研究。
- None.
- None.
- Oral presentation to highlight initial data from ongoing pivotal Phase 2 study of rezatapopt, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors harboring a TP53 Y220C mutation
PRINCETON, N.J., Oct. 13, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that two abstracts have been accepted for oral and poster presentations at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 22-26, 2025 in Boston, MA.
Details for the presentations are as follows:
Oral Presentation
Title: Rezatapopt for locally advanced or metastatic solid tumors with a TP53 Y220C mutation: Initial analysis of the pivotal PYNNACLE Phase 2 trial
Date and Time: Friday, October 24; 10:00 – 11:40 AM ET
Session and Location: Clinical Trials Plenary Session; Level 3, Ballroom AB
Presenter: Alison M. Schram, M.D., Memorial Sloan Kettering Cancer Center
Poster Presentations
Title: Rezatapopt for locally advanced or metastatic solid tumors with a TP53 Y220C mutation: Initial analysis of the pivotal PYNNACLE Phase 2 trial
Date and Time: Friday, October 24; 12:30 – 4:00 PM ET
Session and Location: Poster Session B; Exhibit Hall D
Title: Natural history and prognostic value of TP53 Y220C mutation in advanced solid tumors: A real-world study
Date and Time: Saturday, October 25; 12:30 – 4:00 PM ET
Session and Location: Poster Session C; Exhibit Hall D
About Rezatapopt
Rezatapopt (PC14586) is a first-in-class, small molecule, p53 reactivator designed to selectively bind to the pocket in the p53 Y220C mutant protein, restoring the wild-type tumor-suppressor function. The U.S. Food and Drug Administration granted Fast Track designation to rezatapopt for the treatment of patients with locally advanced or metastatic solid tumors with a p53 Y220C mutation.
About the PYNNACLE Clinical Trial
The ongoing Phase 1/2 PYNNACLE clinical trial is evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation. The primary objective of the Phase 1 portion of the clinical trial was to determine the maximum tolerated dose and recommended Phase 2 dose (RP2D) of rezatapopt when administered orally to patients. Safety, tolerability, pharmacokinetics, and effects on biomarkers were also assessed. The Phase 2 portion is a registrational, single arm, expansion basket clinical trial comprising five cohorts (ovarian, lung, breast, and endometrial cancers, and other solid tumors) with the primary objective of evaluating the efficacy of rezatapopt at the RP2D in patients with TP53 Y220C and KRAS wild-type advanced solid tumors. For more information about the Phase 1/2 PYNNACLE clinical trial, refer to www.clinicaltrials.gov (NCT trial identifier NCT04585750).
About PMV Pharma
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. TP53 mutations are found in approximately half of all cancers. The Company’s co-founder, Dr. Arnold Levine, established the field of p53 biology when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize more than four decades of p53 biology, PMV Pharma combines unique biological understanding with a pharmaceutical development focus. PMV Pharma is headquartered in Princeton, New Jersey. For more information, please visit www.pmvpharma.com.
Contacts
Investors Contact:
Tim Smith
Senior Vice President, Head of Corporate Development and Investor Relations
investors@pmvpharma.com
Media Contact:
Kathy Vincent
Greig Communications
kathy@greigcommunications.com
FAQ
When and where will PMVP present the PYNNACLE Phase 2 initial analysis of rezatapopt?
Who is presenting PMVP's oral presentation on rezatapopt at the AACR-NCI-EORTC conference?
What topics will PMVP cover in its poster presentations at the October 24–25, 2025 conference?
Which mutation cohort is rezatapopt being evaluated in according to PMVP's conference presentations?
How can investors find PMVP's presentation schedule at the AACR-NCI-EORTC conference?
